Curative Biotechnology

How Curative Monetizes Assets Before FDA Approval

About this Event

Curative Biotechnology is developing a potential breakthrough treatment for degenerative eye disease.

Unlike current treatments which require ocular injections, Curative has developed a reformulated version of the FDA-approved drug metformin to treat various types of retinal degeneration under an exclusive worldwide license from the National Eye Institute (NEI) at the NIH.

Metformin has been shown to suppress oxidative stress, improve autophagy in retinal cells, decrease the production of reactive oxygen species that can lead to cell death, and inhibit the epithelial to mesenchymal transition which causes subretinal fibrosis in Dry AMD (age related macular degeneration).

Unlike current treatments which require ocular injections, Curative has developed an eye drop which it believes can get sufficient drug to the back of the eye with topical application to have therapeutic effect.

Curative is preparing for clinical trials for their first indications, intermediate dry AMD and Geographic Atrophy (late stage dry AMD), markets of unmet medical needs worldwide. The NEI will pay for the clinical trial moving forward under an existing CRADA (cooperative research and development agreement) with the Company. Curative is preparing to finalize their GMP manufacturing to produce the drugs for the trials.

Register now to watch our Fireside Chat with the Chairman of the Board and President of Curative Biotech, Paul Michaels, and CEO and General Counsel, Richard Garr, Esq., to hear how this innovative treatment could disrupt a market worth in excess of $11.5B.

Video On Demand

– Recorded

March 26

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.